NASS Call for Abstracts and Proposals

38th Annual Meeting—Los Angeles, CA
October 18-21, 2023

Submission Deadline: February 6, 2023 at 11:59 p.m. CST

Important Information

  • Recommended browsers are Chrome, Firefox, and Internet Explorer.
  • You do not have to be a NASS member to submit an abstract or proposal.
  • Use your NASS username (email address) and password (ID number) to login. Forgotten passwords can be requested from the log-in page. If this is your first interaction with NASS, you can create a new account on the login page.
  • All co-authors and faculty must submit current disclosure. Any author with an out-of-date disclosure will not be allowed to submit; please remove this author or have them update their disclosure before submitting. Submit/update disclosure here.
  • A “Contact Us” link is found at the top of the submission website.

Required Information for Abstract Submissions

Download Full PDF

  • Title
  • Category
  • Keywords (Optional, Maximum of 3)
  • FDA Device/Drug Status: If a device or drug requiring FDA approval is identified as an important component of your presentation, you must indicate the FDA status for the use as discussed in your presentation. You will be required to provide the name of the device(s) and/or drug(s) in your presentation requiring FDA approval, along with the status of Approved, Investigational/Not Approved for use as discussed in the presentation, or Study conducted outside the US/not intended for submission to the FDA. This information will be listed in the meeting’s Final Program and in The Spine JournalTM Meeting Proceedings Supplement.
  • Prior/Future Presentation)
  • Abstract Entry
    • 3,500 character limit; punctuation and spaces count as characters.
    • Presenters may not use their abstract/proposal to market products or services. Use product-based names only when necessary. Use generic names wherever possible.
  • Authors
    • All authors must have records in the NASS database to be added to an abstract. To create a record, visit any NASS log-in page and click “Sign Up as New Contact.” Each record must have a unique email address associated.
    • IMPORTANT: All authors must have disclosures submitted under their unique records to finalize submission at If you are unable to secure all disclosures, remove the author(s) from the abstract and submit. Authors can be added later, as long as disclosure has been submitted.

Required Information for Session Proposals (90 minute symposia)

Download Full PDF

  • Title
  • Description (200-300 words), including any innovative or interactive formats you plan to utilize during the session.
    Possible Formats
  • Educational objectives (3-4)
  • Agenda
  • Suggested faculty with contact information (final faculty selections to be determined by Program Chairs/Committee)

General Submission Policies

  • Each author must submit disclosure under his/her record within the year prior to the proposal submission deadline, using a unique email address/password. If disclosure is not possible by the deadline, please remove the author(s) from your proposal and submit. Authors may be added after proposal acceptance, if disclosure has been submitted within the acceptable timeframe.
  • Prior to submitting your proposal(s), please ensure you and/or one of your team of authors has secured proper funding sources in order to present at the meeting. Presenting authors of all accepted proposal(s) must register for the meeting and are responsible for their own travel expenses as well as the meeting registration fee.
  • NASS reserves the right to withdraw a proposal at any time.
  • All presenters must adhere to the AMA Code of Medical Ethics, Opinion 8.061, “Gifts to Physicians from Industry.” More information may be found here.
  • Medical device companies are prohibited from submitting proposals on behalf of the author(s). Violations subverting the educational content of the meeting and threatening NASS’ ACCME accreditation will be subject to disciplinary action.
  • Presenters may not use their presentation to market products or services. Use generic names wherever possible. Use product-based names only when necessary.